The prevalence of differentiated thyroid cancer (DTC) locally advanced or metastatic refractory to radioactive iodine (RAI) has been increasing in the past decade. The treatments related to this condition are limited and are associated with substantial direct medical costs, low quality of life and survival. The aim of this study was to estimate the cost and effectiveness of sorafenib administrated in radioiodine-refractory DTC patients in Colombia. MethOds: We adapted a Markov Model to simulate the process of radioiodine-refractory DTC patients treated with sorafenib. Clinical data were obtained from a systematic review. Costs were estimated from a standard costing based on expert panel. The primary outcomes were costs and QALYS. We performed one-way sensitivity analysis as well as probabilistic sensitivity analysis based on Monte Carlo simulation of 1000 iterations to explore the uncertainty of the parameters used in the model. Results: The estimated direct medical cost of DTC-RAI was COP $ 575,512 in ambulatory patients. The standard cost of the disease progression was COP $ 2,481,336 in outpatient and COP $ 10,812,295 in inpatient. The progression free survival was 1.30 months for sorafenib and 0.45 for Best Supportive Care (BSC). The monthly costs of treatments were COP $ 20,510,821 and COP $ 9,138,752 for BSC and Sorafenib, respectively. Treatment with sorafenib resulted in additional gains in terms of effectiveness compared to the BSC option. (0.67 QALYs more than treatment with BSC which reported gains of 1.74 QALYs). Moreover, sorafenib results in cost savings for early progression in COP $ 11,299,586 compared to BSC. cOnclusiOns: Sorafenib is a treatment that delays disease progression. Also, given its cost savings results, is a potentially cost effective treatment option in patients with DTC-RAI in Colombia. PCN35 Estudio dE Costo-EfECtividad E imPaCto PrEsuPuEstal dE dENosumab vs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.